Evidence map›Paper›PMID 36950480›Full record

ArticleJournal of clinical and experimental hepatology

Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital.

Sunil Taneja, Rohit Mehtani, Arka De, Suvradeep Mitra, Sahaj Rathi, Nipun Verma, Madhumita Premkumar, Ranjana Minz, Ajay Duseja, Ashim Das and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Extrahepatic autoimmune diseases in autoimmune hepatitis-Are they really uncommon?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sunil TanejaDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Rohit MehtaniDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Arka DeDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Suvradeep MitraDepartment of Immunopathology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Sahaj RathiDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Nipun VermaDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Madhumita PremkumarDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Ranjana MinzDepartment of Immunopathology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Ajay DusejaDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Ashim DasDepartment of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Virendra SinghDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Radha K DhimanDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Yogesh K ChawlaDepartment of Hepatology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Autoimmune liver disease (AILD) comprises of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) with a spectrum of overlap amongst the three. We analyzed the spectrum and treatment outcomes of patients with AILD presenting to a tertiary care center in India. Methods: A retrospective analysis of AILD patients from June 2008 to April 2021 was performed. The diagnosis was based on clinical, biochemical, imaging, serological, and histological characteristics. Eligible patients received treatment depending on the disease stage. Biochemical response to treatment was defined as normalization of AST, ALT, bilirubin, and immunoglobulin G levels at 6 months in AIH, normalization of total bilirubin and/or albumin at 1 year in PBC and decrease in alkaline phosphatase (ALP) levels by 40% in PSC. Results: Two hundred seventy-five patients were analyzed. AIH (58.54%) was most common, followed by an overlap of AIH-PBC (24%) and AIH-PSC (6.54%), PSC (6.18%), and PBC (4.72%). Most patients presented in 3rd or 4th decade, except PBC which occurred predominantly in 5th decade. The majority of patients were females (72.72%). Jaundice was the most common presentation seen in 60% of patients. Cirrhosis was present in 57.47% of patients. Patients with overlap had more pruritus (54.76 vs 6.83%), fatigue (63.1% vs 49.7%), hepatomegaly (52.4% vs 25.5%), and higher ALP (80.9% vs 37.7%) than patients with AIH alone. Acute presentation was seen in 33 patients (13.5%) with most having AIH flare. Five patients had acute liver failure (ALF) and 9 had acute-on-chronic liver failure (ACLF). ALF was associated with 80% mortality while 55.56% of patients with ACLF had a complete biochemical response to immunosuppression. Among patients with AIH and/or overlap who received immunosuppression, a complete biochemical response to immunosuppression was seen in 60.69% of patients. High ALT (OR 1.001 [1.000-1.003], Conclusion: AIH is the most common AILD followed by overlap syndromes, PSC and PBC in our cohort. Biochemical response to immunosuppression is seen in 60% of patients with AIH & low fibrosis score on histopathology predicts a complete response.

Indexed as

ACLF, acute-on-chronic liver failureAIH, autoimmune hepatitisAILD, Autoimmune liver diseasesALF, acute liver failureALP, alkaline phosphataseALT, alanine aminotransferaseAMA, anti-mitochondrial antibodyASMA, anti-smooth muscle antibodyAST, aspartate aminotransferaseautoimmune hepatitiscirrhosisELISA, enzyme-linked immunosorbent assayIBD, inflammatory bowel diseaseIgG, immunoglobulin GINR, international normalized ratioLC-1, liver cytosol 1LKM-1, liver kidney microsomal 1LSM, liver stiffness measurementLT, liver transplantMMF, mycophenolate mofetilMRCP, magnetic resonance cholangiopancreatographyoverlap syndromesPBC, primary biliary cholangitisprimary biliary cholangitisprimary sclerosing cholangitisPSC, primary sclerosing cholangitisSLA, soluble liver antigenUDCA, ursodeoxycholic acidULN, upper limit of normal

Identifiers

PMID36950480
PMCPMC10025584
OpenAlexW4308889668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.